Sumary of mRNA vaccine yields modest cut in COVID-19 infection in veterans with cirrhosis:
- September 10, 2021 2 min read Source/Disclosures Published by: Disclosures: The authors report no relevant financial disclosures.
- Back to Healio A cohort of veterans with cirrhosis who received the mRNA COVID-19 vaccine had a delayed and modest decrease in infection, with an excellent decrease in hospitalizations or death.
- “Patients with cirrhosis have immune dysregulation that is associated with vaccine hyporesponsiveness with several vaccines including hepatitis B and pneumococcal vaccines,” Binu V.
- John, MD, MPH, affiliate associate professor, University of Miami Miller School of Medicine, chief of hepatology, Bruce W Carter VA Medical Center, and colleagues wrote.
- “Therefore, the efficacy of the vaccine in patients with cirrhosis, particularly decompensated cirrhosis, is a significant knowledge gap.
- ” To fill that gap, John and colleagues conducted a retrospective study of 20,037 patients with cirrhosis who received at least one dose of either the Pfizer BNT162b2 mRNA (n = 10, 236) or Moderna mRNA-1273 COVID-19 vaccine (n = 9,801) at the Veterans Health Administration.
- Investigators matched the patients to 20,037 control participants to evaluate the correlations of vaccination with new COVID-19 infection and COVID-19 hospitalization and death.
- COVID-19 infection documented by a positive result by polymerase chain reaction, hospitalization and death due to COVID-19 infection served as the primary outcome.